Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation, Karyopharm, and Sanofi Genzyme.

Cancer Summaries and Commentaries™: Report from San Diego on Advancements in Multiple Myeloma


Release Date: December 30, 2018
Expiration Date: December 30, 2019
Media: Internet - based

Activity Overview

This activity, Cancer Summaries and Commentaries™: Report from San Diego on Advancements in Multiple Myeloma, will provide you with clinically important information about the latest developments in the management of patients with multiple myeloma (MM). Listen to experts as they describe the studies below, and share their insights regarding how these results will impact the care of your patients with MM in the future. In R/R MM, you will explore the treatment of diverse classes of investigational drugs, including a selective inhibitor of nuclear export compound, a Bcl-2 inhibitor, chimeric antigen receptor T-cell therapy, and bispecific T-cell engager antibody therapy. In patients with newly diagnosed disease that is ineligible for transplant, you’ll learn how targeted agents are being combined with existing therapies to improve outcomes. Finally, in patients with newly diagnosed disease that is eligible for transplant, abstracts examine novel regimens in both the induction and consolidation phases. This activity will help you begin now to sharpen your clinical skills for the care of your patients with MM.

Benefits of Completing Activity:

Benefits of participating in the online activity, Cancer Summaries and Commentaries™: Report from San Diego on Advancements in Multiple Myeloma:

  • Familiarize yourself with emerging novel approaches to the treatment of MM, including selective inhibition of nuclear export, chimeric antigen receptor T-cell therapy, and bispecific T-cell engager antibody therapy
  • Improve your understanding of the latest clinical trial data in MM
  • Increase your ability to incorporate practice-changing data into the management of your patients with MM

Acknowledgement of Commercial Support

This activity is supported by educational grants from Celgene Corporation, Karyopharm, and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.


Target Audience

This activity is directed toward medical oncologists and hematologists who treat patients with MM. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the management of patients with MM are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Detail the design, efficacy, and safety endpoints of ongoing and recently completed clinical trials in patients with MM
  • Elaborate on key efficacy and safety results concerning the use of novel strategies in patients with MM and how to incorporate them into practice
  • Place presented clinical trial evidence into the context of evolving treatment paradigms and strategies in the management of patients with MM

Faculty, Staff, and Planners' Disclosures

Faculty

Jesús G. Berdeja, MD
Director, Multiple Myeloma Research
Senior Investigator, Hematologic Malignancies
Sarah Cannon Research Institute
Nashville, TN
 

Disclosures: Grant/Research Support: AbbVie, Amgen, Bluebird, BMS, Celgene, Genentech, Glenmark, Janssen, Novartis, Poseida, Sanofi, Takeda, Teva; Consultant: Celgene, Takeda, Bluebird, Karyopharm, Novartis, Servier, Kite, Sanofi, Prothena

Ajai Chari, MD
Associate Professor
Medicine, Hematology, and Medical Oncology
The Mount Sinai Hospital
New York, NY
 

Disclosures: Grant/Research Support: Takeda, Celgene, Novartis, Janssen; Consultant: Takeda, Celgene, Novartis, Janssen, Bristol-Myers Squibb

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Filter By